Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel. Show more

2 UNIVERSITY PLAZA, HACKENSACK, NJ, UNITED STATES, 07601, Hackensack, NJ, 07601, USA

BIOTECHNOLOGY
HEALTHCARE

Market Cap

184.5M

52 Wk Range

$1.48 - $3.19

Previous Close

$2.22

Open

$2.24

Volume

1,075,616

Day Range

$2.22 - $2.36

Enterprise Value

147.4M

Cash

27.42M

Avg Qtr Burn

-10.4M

Insider Ownership

3.88%

Institutional Own.

22.08%

Qtr Updated

06/30/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

Elelyso® (taliglucerase alpha) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

PRX-115 Details
Chronic refractory gout

Phase 2

Data readout

PRX-119 (DNase I Enzyme) Details
Rare Renal, NETs-Related Diseases

IND

Submission

Alidornase alfa (PRX-110) Details
Genetic disorder, Rare genetic disease, Cystic fibrosis

Failed

Discontinued

OPRX-106 Details
Inflammatory disease, Bowel disorder

Failed

Discontinued